α-Synuclein aggregation, neuroinflammation, and mitochondrial dysfunction contribute to PD, and treatment with Cbx decreases the formation of α-synuclein clumps, resulting in reduced oxidative stress and enhanced mitochondrial function (Thakur and Nehru, 2015). This evidence concerns the gene SNCA and Parkinson disease.